EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aadi Bioscience's enterprise value is $-61.91 Mil.
Aadi Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $24.35 Mil. Therefore, Aadi Bioscience's EV-to-Revenue for today is -2.54.
The historical rank and industry rank for Aadi Bioscience's EV-to-Revenue or its related term are showing as below:
AADI'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2.79 Med: 6.51 Max: 363.75
Current: -2.54
During the past 4 years, the highest EV-to-Revenue of Aadi Bioscience was 363.75. The lowest was -2.79. And the median was 6.51.
AADI's EV-to-Revenue is ranked better than 94.87% of 1034
companies
in the Biotechnology industry
Industry Median: 7.775
vs AADI: -2.54
As of today (2024-04-30), Aadi Bioscience's stock price is $1.92.
Aadi Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.91. Therefore, Aadi Bioscience's PS Ratio for today is 2.12.
Aadi Bioscience EV-to-Revenue Historical Data
The historical data trend for Aadi Bioscience's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aadi Bioscience's EV-to-Revenue
For the Biotechnology subindustry, Aadi Bioscience's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aadi Bioscience's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aadi Bioscience's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aadi Bioscience's EV-to-Revenue falls into.
Aadi Bioscience's current Enterprise Value is $-61.91 Mil.
Aadi Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aadi Bioscience's share price for today is $1.92.
Aadi Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aadi Bioscience EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aadi Bioscience's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aadi Bioscience (Aadi Bioscience) Business Description
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AADI has been successfully added to your 